Honigman represents Gemphire Therapeutics Inc. in $30 million IPO
Honigman Miller Schwartz and Cohn LLP advised Gemphire Therapeutics Inc. on its $30 million initial public offering. The company's common stock now trades on The Nasdaq Global Market under the symbol "GEMP."
Jefferies and RBC Capital Markets acted as joint book-running managers for the offering. Canaccord Genuity acted as co-lead manager and Laidlaw & Company (UK) Ltd. and LifeSci Capital acted as co-managers.
Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease, and nonalcoholic fatty liver disease.
The Honigman corporate and securities team advising Gemphire Therapeutics Inc. included Phillip D. Torrence, Meredith Ervine, Gabrielle Sims, Joscelyn Boucher, Cindy Bott and Stephanie Swan.